QBiotics announces clinical collaboration with MSD targeting unresectable melanoma
13 August 2020
- MSD collaboration to investigate QBiotics’ lead molecule tigilanol tiglate in combination with KEYTRUDA® (pembrolizumab)
- Tigilanol tiglate is a novel, small molecule that is being developed as an intratumoural treatment for solid tumours
- Melanoma is the second human application being pursued for tigilanol tiglate, following on from the Company’s ongoing Phase I/II study in head and neck squamous cell carcinoma.